"Claude Goes to the Lab"... Anthropic Launches Life Sciences-Focused Tools

by Lee Seunghyeong

Published 21 Oct.2025 08:46(KST)

"Leveraging Large-Scale Data for Protein Sequence Analysis and More"

Anthropic, a U.S.-based artificial intelligence (AI) startup, has launched an AI service specialized for life sciences research.

Reuters Yonhap News

On October 20 (local time), Anthropic announced the introduction of "Claude for Life Sciences," a service based on its advanced AI model. Through this service, the company aims to support the entire process of life sciences research with AI technology, from the early stages of research to technology transfer and commercialization.

Anthropic explained that it has added several "connector" features to link its best-performing AI model, Claude Sonnet 4.5, to scientific platforms, and has introduced various "agent skills" to enhance task execution capabilities.

One of the connector features, BioRender, helps integrate Claude with verified scientific diagrams, icons, and templates. Another, PubMed, allows users to access millions of biomedical research papers and clinical study materials.

Among the agent skill tools, Claude offers a "protocol generation" feature that drafts research protocols and standard operating procedures, a "bioinformatics and data analysis" feature that processes and analyzes genome data, and a function that identifies relevant regulatory requirements and drafts documents for submission to authorities.

Eric Kauderer-Abrams, Anthropic's head of life sciences, said, "This is a turning point where we have decided to make this field a major investment area," adding, "Just as coding work is now performed on Claude, we hope that a significant portion of life sciences work worldwide will be carried out using Claude." He continued, "Our goal is to provide biologists with the same experience that software engineers have when generating code," emphasizing that the AI model can leverage large-scale public data for tasks such as genome and protein sequence analysis.

However, he clarified that he does not harbor the "illusion" that AI will magically overcome the physical limitations of scientific research, adding, "A clinical trial that takes three years will not suddenly be completed in a month."